June 2023 news roundup
Imagen Therapeutics asset acquisition
We were delighted to announce the acquisition of the scientific assets of Imagen Therapeutics Limited from its appointed liquidators.
UK pharmaceutical services company Imagen offered personalised cancer treatment through the collection and use of well-characterised, patient-derived cells.
The company collected samples from patients over a number of years across a wide variety of cancers and was able to build a unique ‘biobank’ of human-derived cells and provide services to the global pharmaceutical industry for preclinical screening of drug candidates.
Read more about the news here.
ValiRx shareholder Q&A
On Wednesday 14 June, we held our investor webinar presentation at MediCity, Nottingham in which we updated shareholders, stakeholders, and colleagues on ValiRx’s recent achievements and the progress of Inaphaea BioLabs, as well as providing an overview of Imagen Therapeutics.
You can watch the webinar on our website here.
Annual general meeting
We were pleased to welcome ValiRx shareholders to our AGM, held in London on Wednesday 28 June.
Catch up on the AGM and Q&A session here.
Update on the proposed sub-license of VAL201
We also announced a change to the terms to the Letter of Intent signed with TheoremRx Inc.
The exclusivity provided has been restricted geographically and no longer covers the Greater China region. Until further review, exclusivity remains in place for TheoremRx for all other regions.
The LOI and proposed Licence Agreement remain non-binding and there is no guarantee that this Licence Agreement will be executed or that it will generate material revenues within the expected timeframe or at all.
Read more about the announcement here.
Expanded evaluation agreement with the University of Barcelona
Earlier this month, we announced the expanded evaluation agreement with the University of Barcelona. The agreement had been expanded to a broader collaboration including additional modules targeting KRAS (Kirsten RAt Sarcoma) as possible drugs for treating cancer.
The University of Barcelona has an active research group working in this area and has been awarded a grant to further study the effects of the same lead series. ValiRx has entered into an expansion of the initial evaluation agreement to continue to work alongside the recently funded Barcelona research team to build a broader understanding of the biological activity of the drug candidates.
Watch Dr Suzy Dilly's announcement video with BRR Media here.
